Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9220321 | 1.00 | TDP1 (0.46) | TDP1MEN1CYP2D6HTTKMT2A | |
| SCHEMBL25303957 | 1.00 | TDP1 (0.46) | TDP1MEN1CYP2D6HTTKMT2A | |
| SCHEMBL7266955 | 0.78 | TDP1 (0.54) | TDP1MMP9MMP1MMP2MMP3 | |
| SCHEMBL7773761 | 0.78 | ALOX5 (0.43) | TDP1MEN1CYP2D6HTTKMT2A | |
| 2-Ethylhexanoic Acid SCHEMBL4018852 | 0.75 | CA2 (0.43) | TDP1TAS1R3TAS1R1MMP2MMP3 | |
| SCHEMBL490213 | 0.74 | THRB (0.50) | TAS1R3TAS1R1THRBATMAKR1C3 | |
| SCHEMBL4879128 | 0.74 | THRB (0.50) | TAS1R3TAS1R1THRBATMAKR1C3 | |
| SCHEMBL4906426 | 0.74 | THRB (0.50) | TAS1R3TAS1R1THRBATMAKR1C3 | |
| SCHEMBL2490383 | 0.74 | ALOX5 (0.54) | TDP1LMNATHRBATM | |
| SCHEMBL5198950 | 0.73 | TDP1 (0.56) | TDP1TAS1R3TAS1R1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024429-A2 | UV COMPOSITIONS HAVING LOW ACTIVE CONCENTRATIONS AND HIGH IN VIVO SPF | The Procter & Gamble Company (US) | 2016-06-01 | — | — | EP | claimed |
| US-9044405-B2 | Composition having a reduced exotherm in actinic curing of urethane (meth)acrylate oligomers on fingernails | O P I PRODUCTS, INC. (US) | 2015-06-02 | — | — | US | claimed |
| WO-2015013198-A2 | UV COMPOSITIONS HAVING LOW ACTIVE CONCENTRATIONS AND HIGH IN VIVO SPF | THE PROCTER & GAMBLE COMPANY (US) | 2015-01-29 | — | — | WO | claimed |
| US-20150023895-A1 | UV Compositions Having Low Active Concentrations and High In Vivo SPF | THE PROCTER & GAMBLE COMPANY | 2015-01-22 | — | — | US | claimed |
| WO-2014134009-A1 | COMPOSITION HAVING A REDUCED EXOTHERM IN ACTINIC CURING OF URETHANE (METH)ACRYLATE OLIGOMERS ON FINGERNAILS | O P I PRODUCTS, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140242011-A1 | COMPOSITION HAVING A REDUCED EXOTHERM IN ACTINIC CURING OF URETHANE (METH)ACRYLATE OLIGOMERS ON FINGERNAILS | O P I PRODUCTS, INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-5468492-A | Plant extract for treatment of hair loss | BIOGAL GYOGYSZERGYAR RT (HU) | 1995-11-21 | — | — | US | claimed |
| US-12396965-B2 | Putrescine topical barrier formulation | VIVIER CANADA INC. (CA) | 2025-08-26 | — | — | US | disclosed |
| US-20240293340-A1 | PUTRESCINE TOPICAL BARRIER FORMULATION | VIVIER CANADA INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| US-20230321006-A1 | PUTRESCINE TOPICAL BARRIER FORMULATION | VIVIER CANADA INC. (CA) | 2023-10-12 | — | — | US | disclosed |
| US-20210251920-A1 | PUTRESCINE TOPICAL BARRIER FORMULATION | VIVIER CANADA INC. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-20200281872-A1 | PUTRESCINE TOPICAL BARRIER FORMULATION | VIVIER CANADA INC. (CA) | 2020-09-10 | — | — | US | disclosed |
| US-20190314299-A1 | PUTRESCINE TOPICAL BARRIER FORMULATION | VIVIER CANADA INC. (CA) | 2019-10-17 | — | — | US | disclosed |
| US-20150023895-A1 | UV Compositions Having Low Active Concentrations and High In Vivo SPF | THE PROCTER & GAMBLE COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20150023895-A1 | UV Compositions Having Low Active Concentrations and High In Vivo SPF | THE PROCTER & GAMBLE COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2014134009-A1 | COMPOSITION HAVING A REDUCED EXOTHERM IN ACTINIC CURING OF URETHANE (METH)ACRYLATE OLIGOMERS ON FINGERNAILS | O P I PRODUCTS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140242011-A1 | COMPOSITION HAVING A REDUCED EXOTHERM IN ACTINIC CURING OF URETHANE (METH)ACRYLATE OLIGOMERS ON FINGERNAILS | O P I PRODUCTS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-5468492-A | Plant extract for treatment of hair loss | BIOGAL GYOGYSZERGYAR RT (HU) | 1995-11-21 | — | — | US | disclosed |
| EP-0497952-A1 | COMPOSITION FOR THE TOPICAL TREATMENT OF PSORIASIS | BIOGAL GYOGYSZERGYAR RT. (HU) | 1992-08-12 | — | — | EP | disclosed |
| WO-1992003142-A1 | COMPOSITION FOR THE TOPICAL TREATMENT OF PSORIASIS | BIOGAL Gyógyszergyár Rt. (HU) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023895-A1 | UV Compositions Having Low Active Concentrations and High In Vivo SPF | F10, PAH, RAD50 | TDP1 826/4885MEN1 3948/4885CYP2D6 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.